Q-omics provides the consensus-scored ELOVL5 profile across patient tissues and cancer cell-line models. ELOVL5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ELOVL5 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ELOVL5 RNA expression shows 19,735 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where ELOVL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOVL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOVL5 survival associations across molecular data types. ELOVL5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOVL5 RNA expression–survival associations across cancer types. High ELOVL5 expression shows unfavorable associations in KIRP, MESO, BLCA and SARC, but favorable associations in UCEC and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ELOVL5 RNA expression.
This table summarizes ELOVL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ELOVL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOVL5 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, KIRP, LIHC and HNSC. The KIRC box plot shows higher ELOVL5 RNA expression in tumor versus normal tissue (log2 FC = +1.171, t-test p < 0.001).
This table shows molecular features associated with ELOVL5 in patient tissues and cancer cell lines. In patient samples, ELOVL5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ELOVL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
